A
Marcus Reynolds
58 yr Male MRN 004821
Messages
Calendar
Tasks
Orders
Flags
Dr. S. Aggarwal
Active Dx
T2DM
HTN
Heart Failure
Obesity
Inactive DX
GERD
Resolved: 6/15/2026
Anxiety
Resolved: 6/15/2026
DVT
Resolved: 6/15/2026
Medications
Active
Metformin 500mg BID
Lisinopril 10mg QD
Lantus 30 units QD
Carvedilol 6.25mg BID
Inactive
Metroprolol 50mg BID
Lorazepam 1mg PRN
Surgeries
Appendectomy
6/15/2026
CABG x 3
6/15/2026
Family History
Father: James R.
T2DM
Mother: Carol R.
Breast Cancer
Social History
Non Smoker
Former
Quit 2015
Alcohol Occassional
2-3 Drinks/week
Lives with Spouse
Former
Quit 2015
Profession
Retired
Allergies
Penicillin
Anaphylaxis
Sulfa Drugs
Anaphylaxis
Current State
30D
90D
6M
1Y
All
Type II Diabetes
Worsening
A1c
12.1
%
8.1
9.2
A1c
12.1
%
8.1
9.2
Metformin
Lisinopril
Lantus
Glycemic control worsening despite stable regimen.
Hypertension
Stable
A1c
12.1
%
8.1
9.2
A1c
12.1
%
8.1
9.2
Metformin
Lisinopril
Lantus
Glycemic control worsening despite stable regimen.
Heart Failure
Worsening
A1c
12.1
%
8.1
9.2
A1c
12.1
%
8.1
9.2
Metformin
Lisinopril
Lantus
Glycemic control worsening despite stable regimen.
Longitudinal Disease Engine
30D
90D
6M
1Y
KPIs
A1c
Weight
Fasting Glucose
Events:
Click for before/after details
Semaglutide Jan 4
Exercise Jan 18
Sleep Apr 2
CHF Admit Feb 11
Driver Analysis
A1c
Weight
Fasting Glucose
Positive Contributors
Body Weight
Strong Evidence
0.4
%
Metformin Dosage Change
Weak Evidence
6/16/2026
0.4
%
Exercise Frequency
Strong Evidence
1.2
%
Dietary Adherence
Weak Evidence
6/10/2026
0.7
%
Sleep Quality
Weak Evidence
0.3
%
Negative Contributors
Body Weight
Strong Evidence
0.4
%
Metformin Dosage Change
Weak Evidence
6/16/2026
0.4
%
Sedentary Hours
Strong Evidence
0.9
%
Carbohydrate Intake
Weak Evidence
6/12/2026
0.5
%
Clinical History
All
Medications
Behaviour
Labs
Hospitalizations
Flags
Diagnostics
Jan 12
Jan 24
Feb 2
Feb 16
Mar 5
Mar 18
Apr 2
Apr 20
May 8
Jun 1
Jun 16
Jul 11
Medication
Semaglutide Initiated
0.5 mg · Weekly · GLP-1 Agonist
Lab
Baseline A1c Recorded
A1c 9.4% — starting point
Behaviour
Exercise Improved
Steps ↑ 2,200 → 6,800/day
Flag
A1c Worsening Flagged
3-point rise from baseline
Behaviour
Sleep Disruption Noted
Avg sleep dropped to 4.8h
Lab
Weight Plateau
No change 4-week window
Medication
Dose Titrated
1.0 mg · Weekly · GLP-1 Agonist
Flag
GI Side Effects Reported
Nausea · Mild · Self-resolving
Lab
A1c Improved
9.1% → 8.3% reduction
Behaviour
Sleep Score Increased
Avg 5.2h → 7.1h nightly
Flag
BP Elevation Noted
145/92 mmHg on 3 readings
Lab
Lipid Panel Ordered
LDL 142 mg/dL — borderline
Lab
Fasting Glucose Down
186 → 142 mg/dL
Medication
Metformin Increased
1000 mg · Twice Daily
Behaviour
Dietary Adherence Improved
Carb intake ↓ 280 → 160g/day
Lab
HbA1c Target Reached
7.8% — within goal range
Medication
Semaglutide Continued
Maintenance dose confirmed
Behaviour
Exercise Goal Met
150 min/week sustained
T2DM
Trends
Vitals & Labs/Imaging
Food
Workout
Sleep
Adherence
KPI Snapshot
CPAP Adherence
12.1
mmHg
8.1
9.2
AHI
12.1
mmHg
8.1
9.2
Avg Sleep
12.1
mmHg
8.1
9.2
SpO2 Nadir
88
%
8.1
9.2
Selected Event Detail
Semaglutide Started Jan 4
Before
8.1
%
A1c
After
12.11
%
A1c
Before
200
lbs
Weight
After
196
lbs
Weight
Before
188
mg/dl
Fasting Glucose
After
200
mg/dl
Fasting Glucose
Selected Event Detail
Semaglutide Started Jan 4
Before
8.1
%
A1c
After
12.11
%
A1c
Before
200
lbs
Weight
After
196
lbs
Weight
Before
188
mg/dl
Fasting Glucose
After
200
mg/dl
Fasting Glucose